The ESMO and NCCN clinical guidelines recommend chemotherapy for stage II CCs patients with high-risk tumor features, such as < 12 LNs, pT4 stage, LVI, high preoperative CEA, and so on [7, 8]. Here, CEACAM5 is linked to neoplasm.